Industry Trends

Amid pandemic, rely on the fundamentals.

Assessing COVID-19’s wide and varied impact on pharma and biotech business in the first half of the year, and how it shapes market prospects ahead.

Multicultural campaigns crafted for diverse populations are insufficiently funded and do not receive the same support as mainstream campaigns, writes Sheila Thorne. While there are plenty of people willing to partner with pharma on these campaigns, will the industry wake up to the changing world ahead?

Looking at four building blocks of success, Wolfram Lux and Simone Seiter investigate what it takes to win and be successful when commercializing an orphan drug

Filippo Petti is CEO of Celyad Oncology tells Pharm Exec how the pandemic has affected his role as a US-based CEO to a Belgian company.

The recent merger of Teledoc and Livongo into a $38 billion titan proves that the market sees opportunity in health tech. Could it be an inflection point in our race towards a digital-first care model, or is this an experiment ahead of its time?

Ferdi Steinmann outlines a few supply chain lessons that all pharma companies can learn from the COVID-19 pandemic.

A look at how pharmaceutical company, Paratek is navigating the launch of a new antibiotic during the COVID-19 pandemic.

Michael Wong talks with Dr. Francesca Gino, Tandon Family Professor of Business Administration at the Harvard Business School, about the advantages of embracing a "rebel mindset."

While HCPs are turning away from in-person meetings with sales reps amidst the COVID-19 pandemic, there are still strategies for them to keep their pipelines full.

A look into the complex battle between pharmaceutical manufacturers and payers for balance between medication access and budget management.

Dr. Manuel Hermosilla shares his thoughts on how the pharmaceutical industry reacts to challenges that arise during trials, specifically during the search for an effective COVID-19 vaccine.

A look at how internship programs in the pharma industry have changed since the start of the COVID-19 pandemic.

EXUMA Biotech's Dr. Greg Frost talks about his work making CAR-T cell therapy readily accessible and affordable.

Addressing the challenges created by virtual meetings with HCPs, what we have learned about virtual meetings so far, and a look into the future.

In adjusting to the long-term aftershocks from the coronavirus pandemic, pharma companies will need to focus on change in three core areas.

Patrick Soon-Shiong, the billionaire biotech entrepreneur and owner of NantWorks, a network of health startups, discusses his companies’ COVID-19 vaccine candidate and its “fighting chance” to outsmart the virus’s hidden tricks through merging supercomputing and modernized DNA delivery.

While exposing gaps in the way pharma acquires and uses data, the pandemic has also fostered a new spirit of information sharing that bodes well for future collaborations.

Several months into the COVID-19 pandemic, this article takes a look back at how the launches of new oncology therapies have been impacted.

Andrew Hood and Cliodhna McDonough look at the key issues necessary to support business and the community in developing a long-term and sustainable response to the challenges highlighted by COVID-19.

Jim and Cindy DiBiasi, co-founders of 3D Communications, talk about how to prepare for virtual high-level meetings, such as important regulatory presentations and keynote addresses, in the wake of COVID-19.

Our 20th annual listing highlights brand surges, new ranking battles, and M&A-sparked upswings, but in the shadow of COVID-19, a peek behind the numbers also tells another story.

Pharma is boosting outreach and its image, as the industry faces a defining period in its quest to sway the tide of public perception.

Considerations for biopharma to transform itself beyond the COVID-19 crisis, by Arda Ural.

Every major pharma company undertakes some form of diversity and inclusion work. However, that doesn’t mean it’s reaching the decision-makers, writes Stephen Frost.